Skip to main content

Table 1 Clinical and other relevant characteristics (demographic, lung function, asthma features, comorbidity etc.) of the cohort (at baseline). SD- standard deviation, M- male, F- female, BMI- body mass index, AR- allergic rhinitis, AD- atopic dermatitis, GERD- gastroesophageal reflux disease, RI- reflux index, OSA- obstructive sleep apnoea, AHI- apnoea/hypopnea index, IgE- immunoglobulin E, WBC- white blood cells, hsCRP- high-sensitivity C-reactive protein. Percentile of BMI- underweight (≤ 5), normal (5–85), overweight (86–94), obese (≥ 95)

From: Treatment outcome clustering patterns correspond to discrete asthma phenotypes in children

Age (years)- (mean, SD) 9.97 (3.97)
M- 9.68 (3.93) F- 10.44 (4.01)
Gender (M/F)- N (%) M 223 (61.10) F 142 (38.90)
Percentile of BMI- N (%) Underweight 11 (3.01)
Normal 253 (69.32)
Overweight 50 (13.70)
Obese 51 (13.97)
Duration of disease (years)- mean (SD) 3.27 (2.83) N = 302
Comorbidities- N (%), mean (SD) AR 312 (85.48)
AD ever 101 (27.67)
AD currently 23 (6.33)
GERD, RI score 101 (27.82), 9.10 (SD- 11.19)
OSA, AHI 14 (3.84), 0.57 (SD- 2.84)
Atopy (yes/no)- N (%) Yes 319 (87.40)
No 46 (12.60)
Total IgE (kIU/l)- mean (SD) 614.54 (1145.62), N = 351
Eosinophil count (absolute)- median (SD) 416.35 (341.27), N = 355
Neutrophil count (% of total WBC)- mean (SD) 49.76 (12.86), N = 364
hsCRP (mg/l)- mean (SD) 2.23 (9.30), N = 311
Lung FENO (ppb)- mean (SD) 20.49 (20.07), N = 350
% of FEV1 predicted- mean (SD) 87 (17.14)
% of MEF50 predicted- mean (SD) 88 (23.11)